Acute polyneuropathy: a serious complication of levodopa/
/carbidopa intestinal gel treatment for Parkinson's Disease

J 2024

Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson's Disease

HAVRANKOVA, Petra; Jan ROTH; Vaclav CAPEK; Jiri KLEMPIR; Marek BALÁŽ et. al.

Základní údaje

Originální název

Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson's Disease

Autoři

Vydání

Neurologia i neurochirurgia polska, GDANSK, VIA MEDICA, 2024, 0028-3843

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30210 Clinical neurology

Stát vydavatele

Polsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.600

Kód RIV

RIV/00216224:14110/24:00138483

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.5603/pjnns.100132

UT WoS

001360325600001

EID Scopus

2-s2.0-85213726825

Klíčová slova česky

acute polyneuropathy; Parkinson's Disease; levodopa/carbidopa intestinal gel; levodopa equivalent daily dose

Klíčová slova anglicky

acute polyneuropathy; Parkinson's Disease; levodopa/carbidopa intestinal gel; levodopa equivalent daily dose

Štítky

14110127, CZECRIN, Excelence Science, FNUSA, RIV, rivok, user, článek v časopise

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 5. 2. 2025 13:24, Mgr. Tereza Miškechová

Anotace

V originále

Aim of study. To determine whether a high dose of levodopa-carbidopa intestinal gel (LCIG), expressed as levodopa equivalent daily dose (LE daily dose), is a risk factor for acute polyneuropathy in patients treated with LCIG. Clinical rationale for study. Treatment with LCIG is an effective device-assisted therapy in the advanced stages of Parkinson's Disease (PD). Polyneuropathy is a well-known complication of PD treatment. Patients treated with oral levodopa usually suffer from sub-clinical or mild chronic sensory polyneuropathy. However, severe acute polyneuropathy occurs in patients treated with LCIG, which is causally related to the treatment and leads to its immediate discontinuation.The etiology is not yet clear, but some patients with acute polyneuropathy have been given high doses of LCIG. Material and methods. A retrospective multicentre study of patients treated with LCIG was performed. Patients with acute polyneuropathy were subjected to a detailed analysis including statistical processing. Results. Of 183 patients treated with LCIG in seven centres, six patients (five females, median age 63 years) developed acute polyneuropathy with LCIG discontinuation.The median (interquartile range) initial and final LE daily dose in patients with and without acute polyneuropathy was 3,015 (2,695-3,184) and 1,898 (1,484-2,167) mg, respectively.The final LE daily dose of 2,605 mg cut-off had 83% sensitivity and 93% specificity for the prediction of acute polyneuropathy. Conclusions and clinical implications. The risk of acute polyneuropathy in LCIG-treated patients was associated with a daily LE dose of greater than 2,605 mg or with more than a 62% increase in the daily LE dose during LCIG treatment.

Návaznosti

LX22NPO5107, projekt VaV

Název: Národní ústav pro neurologický výzkum

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Národní ústav pro neurologický výzkum, 5.1 EXCELES

90249, velká výzkumná infrastruktura

Název: CZECRIN IV

Citovat

HAVRANKOVA, Petra; Jan ROTH; Vaclav CAPEK; Jiri KLEMPIR; Marek BALÁŽ; Irena REKTOROVÁ; Vladimir HAN; Matej SKORVANEK; Karin GMITTEROVA; Michal MINAR; Peter VALKOVIC; Michaela KAISEROVA; Petr KANOVSKY; Milan GROFIK; Egon KURCA; Jan NECPAL a Robert JECH. Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson's Disease. Neurologia i neurochirurgia polska. GDANSK: VIA MEDICA, 2024, roč. 58, č. 6, s. 586-592. ISSN 0028-3843. Dostupné z: https://doi.org/10.5603/pjnns.100132.

@article{2468182,
   author = {Havrankova, Petra and Roth, Jan and Capek, Vaclav and Klempir, Jiri and Baláž, Marek and Rektorová, Irena and Han, Vladimir and Skorvanek, Matej and Gmitterova, Karin and Minar, Michal and Valkovic, Peter and Kaiserova, Michaela and Kanovsky, Petr and Grofik, Milan and Kurca, Egon and Necpal, Jan and Jech, Robert},
   article_location = {GDANSK},
   article_number = {6},
   doi = {https://doi.org/10.5603/pjnns.100132},
   keywords = {acute polyneuropathy; Parkinson's Disease; levodopa/carbidopa intestinal gel; levodopa equivalent daily dose},
   language = {eng},
   issn = {0028-3843},
   journal = {Neurologia i neurochirurgia polska},
   title = {Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson's Disease},
   url = {https://journals.viamedica.pl/neurologia_neurochirurgia_polska/article/view/100132/80387},
   volume = {58},
   year = {2024}
}

TY  - JOUR
ID  - 2468182
AU  - Havrankova, Petra - Roth, Jan - Capek, Vaclav - Klempir, Jiri - Baláž, Marek - Rektorová, Irena - Han, Vladimir - Skorvanek, Matej - Gmitterova, Karin - Minar, Michal - Valkovic, Peter - Kaiserova, Michaela - Kanovsky, Petr - Grofik, Milan - Kurca, Egon - Necpal, Jan - Jech, Robert
PY  - 2024
TI  - Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson's Disease
JF  - Neurologia i neurochirurgia polska
VL  - 58
IS  - 6
SP  - 586-592
EP  - 586-592
PB  - VIA MEDICA
SN  - 00283843
KW  - acute polyneuropathy
KW  - Parkinson's Disease
KW  - levodopa/carbidopa intestinal gel
KW  - levodopa equivalent daily dose
UR  - https://journals.viamedica.pl/neurologia_neurochirurgia_polska/article/view/100132/80387
N2  - Aim of study. To determine whether a high dose of levodopa-carbidopa intestinal gel (LCIG), expressed as levodopa equivalent daily dose (LE daily dose), is a risk factor for acute polyneuropathy in patients treated with LCIG. Clinical rationale for study. Treatment with LCIG is an effective device-assisted therapy in the advanced stages of Parkinson's Disease (PD). Polyneuropathy is a well-known complication of PD treatment. Patients treated with oral levodopa usually suffer from sub-clinical or mild chronic sensory polyneuropathy. However, severe acute polyneuropathy occurs in patients treated with LCIG, which is causally related to the treatment and leads to its immediate discontinuation.The etiology is not yet clear, but some patients with acute polyneuropathy have been given high doses of LCIG. Material and methods. A retrospective multicentre study of patients treated with LCIG was performed. Patients with acute polyneuropathy were subjected to a detailed analysis including statistical processing. Results. Of 183 patients treated with LCIG in seven centres, six patients (five females, median age 63 years) developed acute polyneuropathy with LCIG discontinuation.The median (interquartile range) initial and final LE daily dose in patients with and without acute polyneuropathy was 3,015 (2,695-3,184) and 1,898 (1,484-2,167) mg, respectively.The final LE daily dose of 2,605 mg cut-off had 83% sensitivity and 93% specificity for the prediction of acute polyneuropathy. Conclusions and clinical implications. The risk of acute polyneuropathy in LCIG-treated patients was associated with a daily LE dose of greater than 2,605 mg or with more than a 62% increase in the daily LE dose during LCIG treatment.
ER  -

HAVRANKOVA, Petra; Jan ROTH; Vaclav CAPEK; Jiri KLEMPIR; Marek BALÁŽ; Irena REKTOROVÁ; Vladimir HAN; Matej SKORVANEK; Karin GMITTEROVA; Michal MINAR; Peter VALKOVIC; Michaela KAISEROVA; Petr KANOVSKY; Milan GROFIK; Egon KURCA; Jan NECPAL a Robert JECH. Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson's Disease. \textit{Neurologia i neurochirurgia polska}. GDANSK: VIA MEDICA, 2024, roč.~58, č.~6, s.~586-592. ISSN~0028-3843. Dostupné z: https://doi.org/10.5603/pjnns.100132.

Přehled o publikaci